(Q37960157)

25 August 2017

CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies (English)

1 reference

25 August 2017

1

1 reference

25 August 2017

Michael Furman

2

1 reference

PubMed ID

22112004

25 August 2017

Eric S Winer

series ordinal

3

1 reference

PubMed ID

22112004

25 August 2017

language of work or name

English

0 references

publication date

24 November 2011

1 reference

Expert Opinion on Investigational Drugs

25 August 2017

1 reference

25 August 2017

21

1 reference

25 August 2017

15-22

1 reference

25 August 2017

1

1 reference

Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing

25 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640318

p110gamma and p110delta isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640318

p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640318

p110δ, a novel phosphoinositide 3-kinase in leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640318

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640318

PI3K/p110{delta} is a novel therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640318

Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640318

High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640318

Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640318

Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640318

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640318

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640318

Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640318

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640318

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640318

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640318

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640318

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640318

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.640318

10.1517/13543784.2012.640318

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

22112004